Abstract
Herein, we disclose a powerful strategy for the functionalization of the antitumor natural alkaloid noscapine by utilizing photoredox/nickel dual-catalytic coupling technology. A small collection of 37 new noscapinoids with diverse (hetero)alkyl and (hetero)cycloalkyl groups and enhanced sp3 character was thus synthesized. Further in vitro antiproliferative activity screening and SAR study enabled the identification of 6o as a novel, potent, and less-toxic anticancer agent. Furthermore, 6o exerts superior cellular activity via an unexpected S-phase arrest mechanism and could significantly induce cell apoptosis in a dose-dependent manner, thereby further highlighting its potential in drug discovery as a promising lead compound.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 230-238 |
| Number of pages | 9 |
| Journal | ACS Medicinal Chemistry Letters |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 8 2024 |
Keywords
- Anticancer Lead Compound
- Drug Discovery
- Noscapine
- Photoredox/Nickel Dual Catalysis
- Structure Modification
ASJC Scopus subject areas
- Biochemistry
- Drug Discovery
- Organic Chemistry
Fingerprint
Dive into the research topics of 'Structural Modification of Noscapine via Photoredox/Nickel Dual Catalysis for the Discovery of S-Phase Arresting Agents'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS